Paige, an AI-based, global leader in digital diagnostics has raised $100M in series-C, Ied by Casdin Capital and Johnson and Johnson Innovation; the strategic venture capital arm of J&J. The participation round also consisted of earlier investors. Paige closed the series-C round on January 14, 2021.
Through the present investment, they are looking to upgrade their AI-based clinical application and bio sketches. Paige alias, global leaders in digital diagnostics, is currently looking to begin some strategic moves through their AI-led products and technology. They will be investing in running their products and ideas in the market through apt sales and marketing strategies.
Paige was founded in 2017 by David Klimstra, Norman Selby, Peter Schüffler, and Thomas Fuchs. The company has pathology products and software for patients and care teams for better diagnostics. Paige’s novel technology to pathologists, enhance their diagnostic confidence and productivity with secure digital pathology solutions.
Paige is transforming the traditional pathology route into a powerful, enhanced, and intuitive diagnostic AI. Let’s get to the table before and know the specifications of the company.
|Company Legal Name||Paige.AI, Inc|
|Founders||David Klimstra, Norman Selby, Peter Schüffler, Thomas Fuchs|
|Founded Date||Feb 2018|
|Headquarters||Greater New York Area, East Coast, Northeastern US|
|Total Funding Amount||$220M|
|Company Type||For Profit|
|Paige Official Address||Paige.AI|
Here is a grid of steps and operations through which Paige is transforming the cancer diagnostics.
Clinical and pharmaceutical AI applications offered by Paige are as follows:
Paige has a secure AI platform that performs multiple secure functions like LIS interoperability, multi-scanner integration, cloud storage, case management, image review through FullFocus and AI application.
Paige Prostate is a suite of AI applications that helps Paige detect suspicious foci, grading, and quantification of tissue, and an indication of PNI in the needle core biopsy of the prostate tissue.
Paige Breast is a suite of AI applications that help pathologists in breast evaluation and detection of breast biopsies and metastases in the lymph nodes of the breast.
Currently, Paige is working with various pharmaceutical companies to build novel prognostic and predictive digital biomarkers by providing services that enable new and effective treatment plans.
Paige’s powerful AI platform improves the molecular characterization of cancer from H&E tissue samples. It aims to discover new, predictive and prognostic biomarkers from the novel treatments held in its vicinity.
The two solutions provided by Paige are clinical and pharma.
Paige has a team of the world’s most talented engineers, scientists, pathologists, and leaders who are working to mend the future of pathology.
PAIGE, aka- “Pathology Artificial Intelligence Guidance Engine,” Supports its mission through
Also, in the values chart, Paige believes to be ADEPT in the mission to transform cancer diagnostics. ADEPT spells as Accountable (owning your role), Disruptive (don’t settle easily), Execution-Focused (strategic execution), Patient Centric and Trusting (to communicate clearly) to win the race in the market and accomplish their long-desired goal.
Product-related query form link: https://paige.ai/contact-us/
Contact Email: email@example.com
Headquarters Address: 11 Time Square, FI 37, New York, NY 10036
Paige is currently expanding through its partnerships and clinical trials and has 1000 labs across 45 countries with a world-leading pathologist network providing reliable diagnostics.
This global diagnostic platform will use the raised amount of $45M in Series-A funding to expand its outreach and develop bio sketches.
Ans: Currently, Paige has 9 investors till now. It includes Casdin Capital and Catalio Capital Management.
Ans: Possible investors of Paige include Imagen Technologies, Inito, and Health at scales technologies.
Ans: Juan Retamero, MD, is the medical director of digital pathology transformation vicinity at Paige.